Neutralizing Antibodies against SARS-CoV-2 in Individuals with Natural Immunity and Vaccinated Individuals Residents of the State of Aragua, Venezuela
Keywords:
SARS-CoV-2, pandemic, neutralizing antibodies, COVID-19, dry immunofluorescence, COVID-19Abstract
The outbreak of the SARS-CoV-2 disease that started in December 2019 has spread worldwide and has become a global pandemic, with over 676 million cases and more than 6 million deaths to date. The rapid spread and the significant damage caused by the virus have caught the attention of healthcare personnel and large corporations, who have sought to control the progression of the disease through the development of various vaccines. One of the goals of vaccine administration is the production of neutralizing antibodies, as they play a key role in the neutralization and elimination of the virus. In this regard, a cross-sectional descriptive study was done to evaluate the presence and concentration of neutralizing antibodies against SARS- CoV-2 using the dry immunofluorescence method in a sample of 48 vaccinated individuals with different doses and anti-SARS-CoV-2 vaccines, these persons also are residents of the state of Aragua. Various variables, such as pre-existing diseases and history of prior infection, were taken into account and obtained through a data collection form, which allowed a comparison of the concentrations of neutralizing antibodies based on the dose and the vaccine administered. With the development of this project, reliable data is now readily available to inform about decision-making regarding the booster effect doses administered over time.
References
Alcamí, J. (2020). Anticuerpos neutralizantes frente al SARS-CoV-2 [Informe en línea]. Disponible: http://hdl.handle.net/20.500.12105/10634 [Consulta: Abril 12, 2022]
American Veterinary Medical Association. (2020). Coronavirus: Detailed taxonomy. [Documento en línea]. Disponible: https://www.avma.org/sites/default/files/2020-02/AVMA-Detailed- Coronoavirus-Taxonomy-2020-02-03.pdf. [Consulta: Abril 12, 2022]
Arcos, R., Camac, C. y Cerron, S. (2023). Prevalencia de anticuerpos neutralizantes para Covid-19 en personas atendidas en el Laboratorio Pribejlab – Huancayo de noviembre a diciembre de 2021. [Documento en línea] Disponible: https://repositorio.continental.edu.pe/bitstream/20.500.12394/13094/5/I V_FCS_508_TE_Arcos_Camac_Cerron_2023.pdf [Consulta: Octubre 25, 2023]
Arkhipova-Jenkins, I., Helfand, M., Armstrong, C., Gean, E. Anderson, J., Paynter, R. et al. (2021). Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living Review. Annals of internal medicine, 174(6), 811–821.
Carballal, G. y Oubiña, JR. (2014). Virología médica. (4ª ed.). Buenos Aires: Corpus Libros médicos y científicos.
Chia, W., Zhu, F., Xiang-Ong, S., Young, B., Fong, S., Le Bert, N., et al. (2021). Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. The Lancet. Microbe, 2(6), e240–e249. https://doi.org/10.1016/S2666-5247(21)00025-2
Fehr, AR. y Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. Methods in molecular biology (Clifton, N.J.), 1282, 1–23. https://doi.org/10.1007/978-1-4939-2438-7_1
Gironzini, P. (2021). Reacciones adversas inmediatas a la vacuna inactivada contra el SARS-CoV-2 BBIBP-CORV en 95 internos de medicina del Hospital III Goyeneche – Minsa, Arequipa, 2021. [Documento en línea] Disponible en: http://hdl.handle.net/20.500.12773/12580 [Consulta: Octubre 25, 2023]
Graepel, KW., Kochhar, S., Clayton, EW. y Edwards, KE. (2020). Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. The Journal of infectious diseases, 222(2), 180–182. https://doi.org/10.1093/infdis/jiaa234
Guo, YR., Cao, QD., Hong, ZS., Tan, YY., Chen, SD., Jin, HJ. et al. (2020).
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Medical Research, 7(1), 11. https://doi.org/10.1186/s40779-020-00240-0.
International Committee on Taxonomy of Viruses. (2022). Virus taxonomy: 2021 release. [Documento en línea]. Disponible: https://talk.ictvonline.org/taxonomy/ [Consulta: Marzo 12, 2022]
Jiménez, E. y Espinoza, C. (2020). Revisión bibliográfica: Tormentas de citoquinas producidas por COVID-19, Revista de investigación y desarrollo I+D, 12(1), 42-49. https:// doi.org/10.31243/id.v12.2020.987
Johns Hopkins University & Medicine (2022). Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). [Documento en línea]. Disponible: https://coronavirus.jhu.edu/map.html. [Consulta: Octubre 26, 2023].
Krause, PR., Fleming, TR., Longini, IM., Peto, R., Briand, S., Heymann, DL. et al. (2021). SARS-CoV-2 Variants and Vaccines. New England Journal of Medicine, 385, 179–186. https://doi.org/10.1056/NEJMsr2105280
Kuba, K., Imai, Y., Rao, S., Huan, Y., Guo, S., Yang, P. et al. (2005). Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 436, 112-116. https://doi.org/10.1038/nature03712
Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P. et al. (2020). Coronavirus infections and immune responses. Journal Medical Virology, 92(1), 424-432.
Miller, DM. y Shakest, DC. (1995). Immunofluorescence Microscopy. In Methods in Cell Biology, 48(1), 365–394.
Miranda, A. y Sangueza, L. (2021). Eficacia y eficiencia de las vacunas Sputnik V y Sinopharm mediante control de anticuerpos neutralizantes en personal de salud de la Caja Petrolera de Salud, La Paz, Bolivia. Respirar, 13, 167-173.
Organización Mundial de la Salud (2020). COVID-19 situation reports. [Documento en línea]. Disponible: https://www.who.int/emergencies/diseases/novel-coronavirus- 2019/situation-reports [Consulta: Noviembre 22, 2021].
Pal, M., Berhanu, G., Desalegn, C., y Kandi, V. (2020). Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus, 12(3), e7423. https://doi.org/10.7759/cureus.7423
Pareja-Cruz, A., Delgado, J., Navarrete-Mejía, P.J., Luque-Espino, J.C. y Gonzáles-Moscoso, J.D. (2021). Detección de anticuerpos neutralizantes en profesionales de la salud vacunados contra el SARS-CoV-2. Horizonte médico (Lima), 21(3), e1543. https://doi.org/10.24265/horizmed.2021.v21n3.02
Picazo, J. (2020). Vacuna frente al COVID-19. Sociedad española de quimioterapia: Infección y vacunas, 34(6), 559-598. https://doi.org/10.37201/req/085.2021
Portela, A. (2020). Anticuerpos neutralizantes en pacientes recuperados de COVID-19. [Documento en línea] Disponible: https://www.sanidad.gob.es/biblioPublic/publicaciones/recursos_propio s/resp/revista_cdrom/Suplementos/Pildoras/pildora7.htm [Consulta: Octubre 26, 2023]
Rodríguez, R., Caeiro, J., Pizzi, H., Gallego, S., Blanco, S., Konigheim, B., et al. (2021). Evaluación de la respuesta de anticuerpos neutralizantes a la vacuna Sputnik V en una cohorte en Córdoba y evaluación de las propiedades neutralizantes de anticuerpos naturales y vacunales frente a la variante Manaos. [Documento en línea]. Disponible: https://rdu.unc.edu.ar/handle/11086/18497. [Consulta: Abril 16, 2022].
Samudrala, KP., Kumar, P., Choudhary, K., Thakur, N., Wadekar, GS., Dayaramani, R. et al. (2020). Virology, pathogenesis, diagnosis and in- line treatment of COVID-19. European Journal of Pharmacology, 883, 173375. https://doi.org/10.1016/j.ejphar.2020.173375
Sociedad Venezolana de Infectología (2022). Vacunación de refuerzo contra COVID-19 en Venezuela. [Documento en línea] Disponible: https://svinfectologia.org [Consulta: Julio 22, 2022]
Soto, A., Charca-Rodríguez, F., Pareja-Medina, M., Fernández-Navarro, M., Altamirano-Cáceres, K., Sierra, E. et al. (2021). Evaluación de la respuesta humoral inducida por la vacuna BBIBP-CorV mediante la determinación de anticuerpos neutralizantes en personal sanitario peruano. Revista Peruana de Medicina Experimental y Salud Pública, 38(4): 493-500. https://doi.org/10.17843/rpmesp.2021.384.9244
Xu, XW., Wu, XX., Jiang, XG., Xu, KJ., Ying, LJ., Wang, H. et al. (2020).
Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) otside of Wuhan, China: retrospective case series. BMJ (Clinical research ed.), 368, m606. https://doi.org/10.1136/bmj.m606
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Multidisciplinary & Health Education Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
